biostudies-literatureUnknown2(4)Rial CHeparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy, mediated by immunoglobulin G (IgG) antibodies targeting platelet factor 4/heparin (PF4/H) complexes. Prompt and accurate diagnosis is critical to ensure appropriate treatment and improve outcomes. We aimed to evaluate the performance of the rapid chemiluminescent immunoassay (CLIA) HemosIL AcuStar HIT-IgG (Werfen) for detecting IgG anti-PF4/H antibodies for HIT diagnosis compared with the Zymutest HIA IgG (Hyphen BioMed) enzyme-linked immunosorbent assay (ELISA). This single-center retrospective cohort included all patients with suspected HIT (4Ts score >3). CLIA and ELISA were performed and compared, and results were evaluated against the serotonin-release assay. We included 113 patients with susBlood vessels, thrombosis & hemostasis100084https://www.ebi.ac.uk/biostudies/studies/S-EPMC12509767biostudies-literatureEvaluation of an IgG anti-PF4/H chemiluminescent immunoassay in the diagnosis of heparin-induced thrombocytopenia.PMC12509767Piazza JSable SHelley DLillo-Le Louet ALe Beller CSmadja DMRial CLaney MMauge LGendron NSarthou APresot IGodier ADiehl JLNili RfalseEvaluation of an IgG anti-PF4/H chemiluminescent immunoassay in the diagnosis of heparin-induced thrombocytopenia.Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy, mediated by immunoglobulin G (IgG) antibodies targeting platelet factor 4/heparin (PF4/H) complexes. Prompt and accurate diagnosis is critical to ensure appropriate treatment and improve outcomes. We aimed to evaluate the performance of the rapid chemiluminescent immunoassay (CLIA) HemosIL AcuStar HIT-IgG (Werfen) for detecting IgG anti-PF4/H antibodies for HIT diagnosis compared with the Zymutest HIA IgG (Hyphen BioMed) enzyme-linked immunosorbent assay (ELISA). This single-center retrospective cohort included all patients with suspected HIT (4Ts score >3). CLIA and ELISA were performed and compared, and results were evaluated against the serotonin-release assay. We included 113 patients with sus2025-01-01T00:00:00Z2025 Nov2026-06-04T10:20:12.624Z2026-06-04T03:06:04.82ZS-EPMC125097674108045910.1016/j.bvth.2025.100084